Today, an analyst has provided a rating update for Theratechnologies (TH). Analyst Andre Uddin from Mackie Research reiterated a Hold rating, with a C$7 price target.
According to TipRanks.com, Uddin is a 4-star analyst with an average return of 16.1% and a 37.7% success rate. Uddin covers the Healthcare sector, focusing on stocks such as Theratechnologies Inc, Correvio Pharma Corp, and Knight Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Theratechnologies with a C$11.31 average price target, representing a 99.8% upside. In a report issued on July 3, RBC Capital also maintained a Hold rating on the stock with a C$8 price target.
.
The company has a one-year high of C$11.45 and a one-year low of C$5.17. Currently, Theratechnologies has an average volume of 121.2K.
Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). It offers its product under the brand name of EGRIFTA, which approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
The company’s shares closed on Friday at C$5.66, close to its 52-week low of C$5.17.
